Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.35 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 5/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21882009 | 0.86 | ADAMTS5 (0.38) | AHRHTR2CCHRNB2CHRNA4CHEK1 | |
| SCHEMBL22955689 | 0.79 | AKR1B1 (0.39) | AHRHTR2CCA2CA1 | |
| SCHEMBL23920083 | 0.79 | AKR1B1 (0.39) | AHRHTR2CCA2CA1 | |
| SCHEMBL23920182 | 0.79 | AKR1B1 (0.39) | AHRHTR2CCA2CA1 | |
| SCHEMBL28709156 | 0.77 | KLKB1 (0.34) | AHRMAP3K14HTR2CCHRNB2CHRNA4 | |
| SCHEMBL23014371 | 0.76 | CA2 (0.40) | AHRHTR2CCA2CA1KLKB1 | |
| SCHEMBL4968735 | 0.76 | ABCC8 (0.34) | AHRMAP3K14HTR2C | |
| SCHEMBL29481447 | 0.76 | CA2 (0.40) | AHRHTR2CCA2CA1KLKB1 | |
| SCHEMBL22777699 | 0.74 | POLB (0.44) | — | |
| SCHEMBL23013290 | 0.74 | ADAMTS5 (0.40) | KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317102-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ALTOS LABS, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317102-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | AHR 3302/4885MAP3K14 157/4885HTR2C 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.